Published in Curr Oncol on April 01, 2013
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther (2015) 0.87
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? Ther Adv Med Oncol (2016) 0.81
nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings. Exp Hematol Oncol (2017) 0.76
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. Anticancer Drugs (2015) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Paclitaxel (taxol) N Engl J Med (1995) 5.79
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol (2009) 2.23
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer (2007) 1.66
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract (2008) 1.00
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Ann Oncol (2007) 1.12
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol (2006) 1.07
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer (2003) 1.03
Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab. Curr Oncol (2012) 0.89
Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer. Clin Oncol (R Coll Radiol) (2005) 0.82
Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol (2007) 0.75
Production of methanol from biomass waste via pyrolysis. Bioresour Technol (2012) 0.75